Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Language
Publication year range
1.
Am J Health Syst Pharm ; 55(15): 1584-7, 1998 Aug 01.
Article in English | MEDLINE | ID: mdl-9706184

ABSTRACT

The viability of five microorganisms in topotecan 1 mg/mL (as the hydrochloride salt) in sterile water and the stability of the drug were studied. Duplicate portions of topotecan 1 mg/mL were inoculated with Escherichia coli. The process was repeated for Pseudomonas aeruginosa, Staphylococcus aureus, Candida albicans, and Aspergillus niger. Samples were removed from each solution initially and after 6, 16, and 24 hours and 3, 7, 14, 21, and 28 days of incubation at 20-25 degrees C. To test stability, vials of reconstituted topotecan hydrochloride injection were stored at each of three temperatures--5, 25, and 30 degrees C--and other vials were used for time zero analysis. For each temperature, vials were removed at 1, 7, and 14 days and the remaining vials at 28 days for analysis by high-performance liquid chromatography and for visual and pH assessment. P. aeruginosa, S. aureus, and E. coli lost viability at 16 hours, 24 hours, and 28 days, respectively. C. albicans and A. niger did not lose viability, but their numbers did not grow. No differences in color or clarity were observed, and pH was constant. In all solutions, the topotecan concentration was > 98% of the initial concentration. Topotecan 1 mg/mL in sterile water stored at 20-25 degrees C for up t 28 days did not support growth of the five microorganisms studied; in solutions stored at 5, 25, or 30 degrees C for up to 28 days, topotecan 1 mg/mL remained stable.


Subject(s)
Antineoplastic Agents/chemistry , Microbial Sensitivity Tests , Topotecan/chemistry , Aspergillus niger/drug effects , Candida albicans/drug effects , Chromatography, High Pressure Liquid , Colony Count, Microbial , Drug Contamination , Drug Stability , Escherichia coli/drug effects , Injections, Intravenous , Pseudomonas aeruginosa/drug effects , Staphylococcus aureus/drug effects , Temperature
2.
J Pharm Pharmacol ; 50(2): 127-32, 1998 Feb.
Article in English | MEDLINE | ID: mdl-9530978

ABSTRACT

SB 210661, (S)-N-hydroxy-N-[2,3-dihydro-6-(2,6-difluorophenylmethoxy)-3-benzo furanyl]urea, is a potent and selective inhibitor of 5-lipoxygenase. Its aqueous stability was primarily evaluated to support development of analytical methods and formulations. The results also add to the growing database on the stability of N-hydroxyurea compounds. Comparison of the stability of SB 210661 with that of two other N-hydroxyurea-containing compounds, zileuton and Abbott-79175, supported a common primary degradative pathway at pH > 5 and different degradative pathways at pH < 5. The pathway at pH > 5 is consistent with the hydrolysis of the N-hydroxyurea group, whereas for SB 210661, the pathway at pH < 5 is consistent with specific acid-catalysed nucleophilic displacement of the N-hydroxyurea group by water.


Subject(s)
Benzofurans/chemistry , Lipoxygenase Inhibitors/chemistry , Urea/analogs & derivatives , Drug Stability , Hydrogen-Ion Concentration , Hydroxyurea/analogs & derivatives , Hydroxyurea/chemistry , Kinetics , Urea/chemistry , Water
SELECTION OF CITATIONS
SEARCH DETAIL